23andMe has licensed an antibody it developed to treat inflammatory diseases to the Spanish drugmaker Almirall, according to Bloomberg.
"This is a seminal moment for 23andMe," Emily Drabant Conley, the vice president of business development at 23andMe, tells Bloomberg. "We've now gone from database to discovery to developing a drug."